Maravai LifeSciences (NASDAQ:MRVI) Stock Rating Upgraded by Wall Street Zen

Maravai LifeSciences (NASDAQ:MRVI) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday, Wall Street Zen reports.

Several other analysts have also issued reports on MRVI. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maravai LifeSciences in a report on Wednesday, August 26th. UBS Group boosted their target price on Maravai LifeSciences from $2.50 to $8.00 and gave the company a “neutral” rating in a research note on Wednesday, September 9th. TD Cowen assumed coverage on Maravai LifeSciences in a research report on Monday, October 5th. They issued a “buy” rating and a $9.00 target price on the stock. Finally, Wells Fargo & Company upped their target price on Maravai LifeSciences from $5.50 to $6.50 and gave the stock an “overweight” rating in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Maravai LifeSciences currently has an average rating of “Moderate Buy” and an average target price of $7.38.

Maravai LifeSciences Price Performance

Maravai LifeSciences stock opened at $7.52 on Friday. Maravai LifeSciences has a twelve month low of $2.55 and a twelve month high of $9.42. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.98 and a current ratio of 4.05. The firm has a market cap of $1.95 billion, a PE ratio of -17.49 and a beta of 0.61. The firm’s 50 day moving average price is $7.37 and its two-hundred day moving average price is $5.33.

Maravai LifeSciences (NASDAQ:MRVI) last issued its earnings results on Wednesday, November 4th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.03. Maravai LifeSciences had a negative net margin of 30.83% and a negative return on equity of 12.23%. The company had revenue of $45.85 million during the quarter, compared to analyst estimates of $43.56 million. On average, research analysts predict that Maravai LifeSciences will post -0.18 EPS for the current fiscal year.

Institutional Trading of Maravai LifeSciences

Large investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC boosted its holdings in Maravai LifeSciences by 0.9% in the first quarter. Renaissance Technologies LLC now owns 4,264,689 shares of the company’s stock worth $12,069,000 after purchasing an additional 39,600 shares in the last quarter. General American Investors Co. Inc. increased its position in Maravai LifeSciences by 8.3% during the first quarter. General American Investors Co. Inc. now owns 1,716,193 shares of the company’s stock worth $4,857,000 after buying an additional 130,877 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Maravai LifeSciences by 64.8% during the first quarter. Dimensional Fund Advisors LP now owns 1,418,597 shares of the company’s stock worth $4,015,000 after buying an additional 558,050 shares during the last quarter. Brummer Multi Strategy AB raised its holdings in Maravai LifeSciences by 66.0% during the first quarter. Brummer Multi Strategy AB now owns 759,743 shares of the company’s stock valued at $2,150,000 after buying an additional 302,036 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new position in Maravai LifeSciences during the second quarter valued at about $2,230,000. 50.25% of the stock is owned by institutional investors.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc is a life sciences company that provides products and services used in the development, manufacture and quality testing of biopharmaceuticals, vaccines and diagnostic products. The company serves pharmaceutical, biotechnology, academic and other research organizations involved in nucleic acid and biologics development.

Through its TriLink BioTechnologies business, Maravai supplies specialized nucleic acid products and services, including modified nucleotides, messenger RNA-related materials, enzymes and other components used in research and biomanufacturing.